The expanding role of immunopharmacology: IUPHAR Review 16

British Journal of Pharmacology

Volumn 172, Issue 17, 2015, Pages 4217-4227

  Tiligada, Ekaterini ^a,b   Ishii, Masaru ^c   Riccardi, Carlo ^d   Spedding, Michael ^e   Simon, Hans Uwe ^f   Teixeira, Mauro Martins ^g   Landys Chovel Cuervo, Mario ^h   Holgate, Stephen T ⁱ   Levi Schaffer, Francesca ^j  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c OSAKA UNIVERSITY   (Japan)

^d UNIVERSITY OF PERUGIA   (Italy)

^e SPEDDING RESEARCH SOLUTIONS SARL   (France)

^f UNIVERSITY OF BERN   (Switzerland)

^g FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^h FINLAY INSTITUTE   (Cuba)

ⁱ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^j HEBREW UNIVERSITY OF JERUSALEM   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEMTUZUMAB; BOSUTINIB; CABOZANTINIB; CRIZOTINIB; DABRAFENIB; DASATINIB; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ERLOTINIB; GEFITINIB; GOLIMUMAB; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; IMATINIB; INFLIXIMAB; INFLUENZA VACCINE; LAPATINIB; NILOTINIB; NINTEDANIB; OMALIZUMAB; RITUXIMAB; RUXOLITINIB; SECUKINUMAB; SORAFENIB; SUNITINIB; TOCILIZUMAB; TRAMETINIB; UNINDEXED DRUG; VANDETANIB; CYTOKINE; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY;

ALK POSITIVE LUNG CANCER; ARTICLE; ASTHMA; B CELL LYMPHOMA; BEHCET DISEASE; BIOLOGICAL FUNCTIONS; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CHRONIC URTICARIA; CROHN DISEASE; CUTANEOUS MELANOMA; DRUG ACTIVITY; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; FIBROSING ALVEOLITIS; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMATINIB RESISTANT CHRONIC MYELOID LEUKEMIA; IMMUNOPHARMACOLOGY; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; MULTIPLE SCLEROSIS; MYELOFIBROSIS; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; THYROID CANCER; ANIMAL; AUTOIMMUNE DISEASES; CELLULAR IMMUNITY; CLINICAL PHARMACOLOGY; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; TRENDS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CYTOKINES; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; NEOPLASMS; PHARMACOLOGY, CLINICAL;

EID: 84938737975     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13219     Document Type: Article

References (64)

1. Akkoc T, Akdis M, Akdis CA, (2011). Update in the mechanisms of allergen-specific immunotherapy. Allergy Asthma Immunol Res 3: 11-20.
2. Alangari AA, (2010). Genomic and non-genomic actions of glucocorticoids in asthma. Ann Thorac Med 5: 133-139.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The concise guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The concise guide to PHARMACOLOGY 2013/14: nuclear hormone receptors. Br J Pharmacol 170: 1652-1675.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The concise guide to PHARMACOLOGY 2013/14: catalytic receptors. Br J Pharmacol 170: 1676-1705.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013d). The concise guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
7. Almouzni G, Altucci L, Amati B, Ashley N, Baulcombe D, Beaujean N, et al. (2014). Relationship between genome and epigenome-challenges and requirements for future research. BMC Genomics 15: 487.
8. Beck A, Wurch T, Bailly C, Corvaia N, (2010). Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10: 345-352.
9. Breedveld FC, (2000). Therapeutic monoclonal antibodies. Lancet 355: 735-740.
10. Bryant CE, Orr S, Ferguson B, Symmons MF, Boyle JP, Monie TP, (2015). International union of basic and clinical pharmacology. XCVI. Pattern recognition receptors in health and disease. Pharmacol Rev 67: 462-504.
11. Chan AC, Carter PJ, (2010). Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10: 301-316.
12. Chen IF, Fu LW, (2011). Mechanisms of acquired resistance to tyrosine kinase inhibitors. Acta Pharm Sin B 1: 197-207.
13. Chliva C, Aggelides X, Makris M, Katoulis A, Rigopoulos D, Tiligada E, (2015). Comparable profiles of serum histamine and IgG4 levels in allergic beekeepers. Allergy 70: 457-460.
14. Cohen A, (2006). From pharmacology to immunopharmacology. Br J Clin Pharmacol 62: 379-382.
15. Corbisier J, Galès C, Huszagh A, Parmentier M, Springael JY, (2015). Biased signaling at chemokine receptors. J Biol Chem 290: 9542-9554.
16. 1 antihistamines. J Investig Allergol Clin Immunol 16: 3-12.
17. Davies SP, Reddy H, Caivano M, Cohen P, (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
18. Dollery CT, (2014). Lost in Translation (LiT). Br J Pharmacol 171: 2269-2290.
19. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA, (2008). Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453: 1122-1126.
20. Fabbro D, (2015). 25 years of small molecular weight kinase inhibitors: potentials and limitations. Mol Pharmacol 87: 766-775.
21. Fabbro D, Cowan-Jacob SW, Moebitz H, (2015). 10 things you should know about protein kinases' IUPHAR Review 14. Br J Pharmacol 172: 2675-2700.
22. Feldmann M, Maini RN, (2001). Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19: 163-196.
23. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, et al. (2014). Classification of current anticancer immunotherapies. Oncotarget 5: 12472-12508.
24. Gebril A, Alsaadi M, Acevedo R, Mullen AB, Ferro VA, (2012). Optimising efficacy of mucosal vaccines. Expert Rev Vaccine 11: 1139-1155.
25. Holgate ST, (2013). Immune circuits in asthma. Curr Opin Pharmacol 13: 345-350.
26. Kenakin T, Christopoulos A, (2013). Signaling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12: 205-216.
27. Kopf M, Bachmann MF, Marsland BJ, (2010). Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov 9: 703-718.
28. Köhler G, Milstein C, (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.
29. 4 receptor ligands modify vascular histamine levels in normal and arthritic large blood vessels in vivo. Inflammation 38: 949-958.
30. van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG, (2014). Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 15: e315-e326.
31. Leroux-Roels G, (2010). Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28S: 25-36.
32. Loriot Y, Perlemuter G, Malka D, Penault-Lorca F, Boige V, Deutsch E, (2008). Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol 5: 268-278.
33. Marfe G, Di Stefano C, (2014). Bypass mechanisms of resistance to tyrosine kinase inhibition in chronic myelogenous leukaemia. Curr Drug Discov Technol 11: 145-153.
34. Medzhitov R, (2007). Recognition of microorganisms and activation of the immune response. Nature 449: 819-826.
35. Moebitz H, Fabbro D, (2012). Conformational bias: a key concept for protein kinase inhibition. Eur Phar Rev 17: 41-51.
36. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, et al. (2003). Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 33: 1198-1208.
37. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, et al. (2002). Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and Imatinib (STI-571). Cancer Res 62: 4236-4243.
38. 4 receptor signalling by JNJ 7777120 analogues. Br J Pharmacol 170: 78-88.
39. Parsons ME, Ganellin CR, (2006). Histamine and its receptors. Br J Pharmacol 147: 127-135.
40. Patel P, Salapatek AM, (2006). Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev Vaccines 5: 617-629.
41. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res 42 (Database Issue): D1098-D1106.
42. Pelaia G, Vatrella A, Maselli R, (2012). The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 11: 958-972.
43. Rask-Andersen M, Almen MS, Schioth HB, (2011). Trends in the exploitation of novel drug targets. Nat Rev Drug Discov 10: 579-590.
44. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. (1994). Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445.
45. Rosewich M, Lee D, Zielen S, (2013). Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis. Hum Vaccin Immunother 9: 1523-1531.
46. Scalapino KJ, Daikh DI, (2008). CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev 223: 143-155.
47. Schumacher S, Kietzmann M, Stark H, Bäumer W, (2014). Unique immunomodulatory effects of azelastine on dendritic cells in vitro. Naunyn Schmiedebergs Arch Pharmacol 387: 1091-1099.
48. Siebenhaar F, Falcone FH, Tiligada E, Hammel I, Maurer M, Sagi-Eisenberg R, et al. (2015). The search for mast cell and basophil models-are we getting closer to pathophysiological relevance? Allergy 70: 1-5.
49. Simon D, Borradori L, Simon HU, (2013). Glucocorticoids in autoimmune bullous diseases: are neutrophils the key cellular target? J Invest Dermatol 133: 2314-2315.
50. Song DH, Lee JO, (2012). Sensing of microbial molecular patterns by Toll-like receptors. Immunol Rev 250: 216-229.
51. Steinman L, Merrill JT, McInnes IB, Peakman M, (2012). Optimization of current and future therapy for autoimmune diseases. Nat Med 18: 59-65.
52. Sundberg TB, Xavier RJ, Schreiber SL, Shamji AF, (2014). Small-molecule control of cytokine function: new opportunities for treating immune disorders. Curr Opin Chem Biol 23C: 23-30.
53. Tanaka T, Narazaki M, Kishimoto T, (2012). Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 52: 199-219.
54. Thomas ML, (1989). The leukocyte common antigen family. Annu Rev Immunol 7: 339-369.
55. Thomson AW, Turnquist HR, Raimondi G, (2009). Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9: 324-337.
56. Tiligada E, (2012). Editorial: is histamine the missing link in chronic inflammation? J Leukoc Biol 92: 4-6.
57. 4 receptors as novel drug targets. Expert Opin Investig Drugs 18: 1519-1531.
58. Ubersax JA, Ferrell JE Jr, (2007). Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol 8: 530-541.
59. Woodward DF, Jones RL, Narumiya S, (2011). International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 63: 471-538.
60. 4 receptor in immune and inflammatory disorders. Br J Pharmacol 157: 24-33.
61. Zhu J, Yamane H, Paul WE, (2010). Differentiation of effector CD4 T cell populations. Annu Rev Immunol 28: 445-489.
62. IUPHAR Immunopharmacology Section (2015). Introduction [Online]. Available at: http://www.iuphar.us/index.php/sections-subcoms/immunopharmacology (accessed 1/11/2015).
63. IUPHAR/BPS Guide to Pharmacology (2015). Home [Online] Available at: http://www.guidetopharmacology.org/ (accessed 1/11/2015).
64. WHO Model Lists of Essential Medicines (2013). WHO Model Lists of Essential Medicines [Online]. Available at: http://www.who.int/medicines/publications/essentialmedicines/en/index.html (accessed 1/12/2015).